menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

ADMP / Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease progression and reduce replication. I match TEMPOL up against contemporary COVID-19 products. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Adamis

Pharmaceuticals

Market

Continues

Overlook

Tempol

Pharmaceuticals

Tempol s

Potential

Leading

Covid 19

Therapeutic

Stock

ADMP

Posted: Jan 20 2022, 12:20
Author Name: Seeking Alpha
Views: 111923

ADMP News  

Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 15, 2023

Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2023 Earnings Conference Call May 15, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR W more_horizontal

Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 17, 2023

Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q4 2022 Results Conference Call March 16, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR more_horizontal

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

By GlobeNewsWire
March 14, 2023

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primaril more_horizontal

Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News

By InvestorPlace
February 28, 2023

Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News

It's an unusual day for Adamis Pharmaceuticals (NASDAQ: ADMP ) stock traders, to say the least. That's because the company recently announced its inte more_horizontal

Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Robert Uhl - West more_horizontal

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 16, 2022

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2022 Results - Earnings Call Transcript

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2022 Earnings Conference Call May 16, 2022 5:00 PM ET Corporate Participants Robert Uhl - ICR Wes more_horizontal

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

By GlobeNewsWire
May 9, 2022

Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update

SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializ more_horizontal

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 31, 2022

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q4 2021 Results - Earnings Call Transcript more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: